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          Atherosclerosis is the disease related to coronary heart disease and stroke. The initiation of 
atherosclerosis is induced by physical stimuli which is shear stress on the endothelial cells and 
by endothelial activation. Development of atherosclerosis and foam cell formation is highly 
related to lipoprotein metabolism especially the concentration of oxidized low density 
lipoprotein(oxLDL).   
          This essay presents an in-depth review of lipoprotein metabolism, including how 
chylomicron and chylomicron remnant works, how ApoB100 lipoprotein (VLDL, IDL and LDL) 
works, how high density lipoprotein(HDL) and reverse cholesterol transport works, and how 
these lipoproteins interact with each other. Moreover, other species and process which play the 
important role in lipoprotein metabolism such as lipoprotein lipase and beta-oxidation are 
reviewed. 
          Then a model of lipoprotein metabolism based on plasma, liver, adipose and muscle 
compartment is presented. This model was used to analyze how the composition of dietary fat 
affects oxLDL concentration. 
          Palm oil, olive oil and corn oil (enriched in saturated, monounsaturated and omega-6 fatty 
acids) were used as impacts. The result shows that corn oil has the largest amount of both double 
bond and oxidized double bond after meals which suggests that corn oil and other 
polyunsaturated fats are related to atherosclerosis. 
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Chapter 1. Introduction 
1.1 Atherosclerosis 
1.1.1 Overview  
          Atherosclerosis, a disease in which plaques accumulate in subendothelial space, or in 
tunica intima of arteries, is considered as the main factor of peripheral artery disease, coronary 
artery disease and stroke.1,2 Atherosclerotic plaque consists of connective tissue, lipids, 
macrophage cells and immune cells.3,4 The overall atherosclerosis process can be divided into 
several key stages.5 
 
1.1.2 Initiation 
          Initiation of atherosclerosis is due to endothelial dysfunction which leads normal 
endothelial cells lines to become compromised and proinflammatory.6 There are several factors 
that promote endothelial dysfunction including endothelial activation, physical stimuli (shear 
stress) and cytokines.  Endothelial activation, by definition, is the increased expression of cell 
surface adherence proteins such as vascular cell adhesion molecule 1(VCAM-1).5,7 Endothelial 
activation is induced primarily by nuclear factor kappa B(NF-B) which is a group of 
transcription factors and its activation depend on cytokines.8 The physical stimulus that promotes 
endothelial dysfunction is the turbulent flow which commonly occurs at branches and curves of 
artery whereas lamina flow usually occurs at straight smooth artery wall, and this makes 
branches and curves in arteries more susceptible to endothelial dysfunction.9,10 
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1.1.3 Development and form cell formation 
          Endothelial dysfunction will lead to relatively high probability of recruitment, adhesion 
and migration of monocytes into local subendothelial space due to the increased factors 
including adhesion proteins and attractant factors.11-14 Monocytes in the subendothelial space 
then differentiate into macrophages. In artery intima, Macrophages recognize apoB-containing 
lipoproteins including low density lipoprotein(LDL), intermediate density lipoprotein(IDL), very 
low density lipoprotein(VLDL) remnant and chylomicron(CM) by endocytosis through LDL 
receptors(LDLR) on the surface of macrophages. After uptake, the cholesterol ester(CE) from 
apoB-containing lipoproteins is hydrolyzed in the lysosomes of macrophages to free 
cholesterol(FC) which is delivered to the endoplasmic reticulum. In endoplasmic reticulum, FC 
is esterified to CE.15,16 The produced CE is stored in the form of droplets. The number and size 
of droplets inside macrophages is the main indicator of whether these macrophages are converted 
to foam cells.17 Formation of foam cells which have excess CE droplets inside is the next step in 
monocyte recruitment in the overall atherosclerosis process. In normal macrophages, 
accumulating CE in endoplasmic reticulum triggers reduced endocytosis of ApoB-containing 
lipoproteins by downregulating the LDLR in order to prevent foam cell formation. But this CE 
control mechanism only works for LDLR endocytosis process. Modified ApoB-containing 
lipoproteins especially oxidized LDL(oxLDL) are preferentially bound by specific scavenger 
receptors such as CD36 which are not affected by the macrophage CE control mechanism.18,19 
The increased amount of modified ApoB-containing lipoproteins, or increased oxLDL, results in 




1.1.4 Inflammation and thrombus 
          As the number of foam cells increases, the chemoattractant and growth factors derived 
from foam cells also increase.20–23 These chemoattractant and growth factors enhance the 
infiltration of vascular smooth muscle cells(VSMCs) into the tunica intima from the tunica 
media. The infiltrated VSMCs then proliferate and form a fibrous cap that covers the foam 
cells.24 When the foam cells accumulations area gets large enough, it leads to macrophages death 
and efferocytosis to produce a necrotic core inside the area.25,26 In the stable state, the necrotic 
core is small and the fibrous cap is thick enough to prevent rupture. The appearance of specific 
inflammatory factors, with increasing age, enlarges the necrotic core by converting the foam 
cells to their proinflammatory phenotype and increases their susceptibility to apoptosis. 
Meanwhile, the specific inflammatory factors also weaker the fibrous cap which results in a high 
possibility of rupture.27,28 The combination of attenuated fibrous cap and extended necrotic core 
eventually cause the rupture and thrombus by releasing procoagulation components into the 




          Lipoproteins are the primary transporters that deliver cholesterol, triglycerides and other 
nutrients from blood to tissues. Lipoproteins are classified into Chylomicron, very-low-density 
lipoprotein(VLDL), intermediate- low-density lipoprotein(IDL), low-density-lipoprotein(LDL) 
and high-density-lipoprotein(HDL) according to their density. Each lipoprotein has a 
hydrophobic core which is comprised of cholesterol ester(CE) and triglyceride(TG), and 
hydrophilic monolayer membrane which is comprised of phospholipid(PL), free cholesterol(FC) 
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and one or more apolipoproteins. Different types of apolipoproteins including ApoA1, ApoB48, 
ApoB100, ApoC2, ApoC3 and ApoE penetrate the surface of lipoproteins as transmembrane 
proteins. 
 
1.2.2 Species in Lipoproteins 
          Triglycerides are composed of one glycerol and three fatty acids molecules. It is an 
essential component of body fat storage for energy and plays a key role in beta-oxidation to 
produce Acetyl-CoA. Cholesterol is a type of sterol. It is used to synthesize hormones as well as 
to contain cell membrane fluidity. Cholesterol ester is the esterified molecule of cholesterol 
which consists of one cholesterol molecule combined with one fatty acid molecule. 
Phospholipid, the main element of cell membrane besides cholesterol, is made by one glycerol 
molecule, two fatty acid molecules and a phosphate group.  
 
1.2.3 Apolipoproteins in Lipoproteins  
          ApoA1 is the main protein of pre-HDL and mature HDL. It is produced in the liver and 
intestine so ApoA1 also is found in chylomicrons. It associates with lecithin cholesterol 
acyltransferase(LCAT), scavenger receptor1(SR-B1) and ATP-binding cassette protein 
A1(ABCA1) during the reverse cholesterol transport process. ApoB48 is the main protein in the 
chylomicrons and chylomicron remnants and is produced in intestine. Each chylomicron or 
chylomicron remnant only has one ApoB48. ApoB100 is produced in the liver and exists in 
VLDL, IDL and LDL. It mediates lipoprotein endocytosis via recognition by LDL receptor. 
There is only one ApoB100 in each VLDL/IDL/LDL. ApoC2 and ApoC3 are the activator and 
inhibitor of lipoprotein lipase(LPL) that mediate triglyceride hydrolysis process. Both ApoC2 
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and ApoC3 exist in HDL, VLDL and chylomicron.31,32 ApoE, exists in IDL, chylomicron 
remnant and HDL, has the major function promoting lipoprotein endocytosis since it is 
recognized by LDL receptor. 
 CM VLDL IDL LDL HDL 
Volume (L) 8.17E-15 8.70E-17 1.40E-17 8.17E-18 3.20E-19 
Mass (g) 7.60E-12 8.70E-14 1.40E-14 8.50E-15 3.52E-19 
Concentration (nmol/L) 70 90 100 1200 34000 
Molecular Weight (g/mol) 1.50E6 4.00E6 3.50E6 2.75E6 1.75E5 
TG (g) 0.4515 0.99 0.316 0.99 1.49 
PL (g) 0.03675 0.324 0.261 3.63 9.82 
CE (g) 0.021 0.216 0.399 6.93 5.06 

















Table 1. Physical properties and apolipoproteins in the lipoproteins33 
 
1.2.4 Chylomicrons and Chylomicrons Remnants  
          Chylomicrons play a key role in transporting dietary fat from intestine to diverse organs. 
Dietary triglycerides are first hydrolyzed to fatty acids by intestinal lipase in the intestinal lumen. 
Then intestinal cells uptake fatty acids and cholesterol and transfer them to triglyceride and 
cholesterol ester for further circulation. Triglycerides synthesis requires monoacylglycerol 
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acyltransferase(MGAT) and diacylglycerol acyltransferase(DGTA) and cholesterol ester 
synthesis requires ABCA1 in the intestinal cells.34 Triglycerides, cholesterol esters, ApoB48, 
ApoA1 and other components are assembled in the endoplasmic reticulum with the help of 
microsomal triglyceride transfer protein(MTP).35 Then chylomicrons are secreted to lymph and 
finally transported to plasma through thoracic duct.36,37 In the plasma, chylomicrons acquire 
ApoC and ApoE from HDL by cholesterol ester transfer protein(CETP). In this CETP mediates 
exchange process, CETP also transfers cholesterol ester from HDL to chylomicron and transfers 
ApoA1 as well as triglyceride to HDL. The ‘mature’ chylomicrons that have all the apoproteins 
needed are then transported to different organs.38 In muscle and adipose tissue, LPL is 
synthesized and attached on the capillary vessel wall. LPL hydrolyze triglyceride from 
chylomicron to free fatty acids with the help of ApoC2. Muscle cells and adipocytes uptake the 
produced free fatty acids by fatty acid transport protein(FATP) for further metabolism or storage. 
Once the triglyceride concentration inside chylomicron reaches around one fifth of its original 
amount, ApoC3 carried by chylomicrons will cease the hydrolysis and all the ApoC will 
dissociate. These chylomicrons with reduced triglycerides and only ApoB48 and ApoE are called 
chylomicron remnants.39 LDL receptors on the surface of hepatocytes recognize and bind ApoE 
on the chylomicron remnants to promote the endocytosis.40-44 
 
1.2.5 ApoB100-containing Lipoproteins 
          VLDL, IDL and LDL are the ApoB100-containing lipoproteins that deliver triglycerides 
and cholesterol from liver to other organs. Nascent VLDL is assembled in the hepatocyte 
endoplasmic reticulum utilizing the ApoB100, triglycerides, cholesterol esters, phospholipids 
and free cholesterol in the liver. The VLDL synthesis also requires MTP.45,46 After VLDL is 
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secreted into blood stream, it acquires ApoC and ApoE from HDL by CETP transferring. CETP 
also transfers cholesterol esters from HDL to VLDL and triglycerides from VLDL to HDL.47 
Like chylomicrons, triglycerides in VLDL undergo hydrolysis when VLDL binds to lipoprotein 
lipase with the help of ApoC2 in muscle and adipose capillaries. The free fatty acids produced 
then will be taken up by muscle cells and adipocytes for further utilization. The original mature 
VLDL particles are triglyceride-rich micelles with triglycerides being about 55% of the 
composition.48 Once triglycerides in the VLDL are removed and drop to one third of original 
amount by lipoprotein lipase hydrolysis, the VLDL then becomes IDL and ApoC on the it will 
dissociate.49 IDL in the blood stream is either endocytosed by the liver when ApoE on IDL binds 
to LDL receptors on hepatocytes, or further hydrolyzed by hepatic lipase(HL) in the plasma. The 
further hydrolyzed IDL has more triglycerides removed and becomes LDL which is a cholesterol 
ester-rich lipoprotein.50 About 50% of the LDL compositions are cholesterol esters. When IDL 
becomes LDL, ApoE on its surface dissociates. Although LDL doesn’t have ApoE on its surface, 
it could be endocytosed and cleared by LDL receptors since LDL receptors also recognize and 
bind ApoB100. However, the binding affinity between ApoB100 and LDL receptors is much 
lower than that between ApoE and LDL receptors. This results in a long retention time in the 
plasma for LDL since LDL receptors always preferentially bind IDL and chylomicron remnants 
or even VLDL and chylomicrons which have ApoE on their surfaces.51,52 Eventually, the long 
retention time of LDL makes LDL more susceptible to be taken up by macrophages or be 
modified to oxidized LDL(oxLDL) and induce further atherosclerosis.  
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1.2.6 High density lipoprotein 
          HDL plays an important role in the reverse cholesterol transport and cholesterol balance 
since HDL is the main carrier of cholesterol from peripheral tissues to the liver. HDL 
metabolism begins with the synthesis of ApoA1 with LCAT which mainly occurs in the liver. 
ApoA1 is the main structural and functional protein of HDL.53,54 Newly produced ApoA1 
acquires cholesterol and phospholipid from peripheral tissues to form the nascent HDL with 
basic structure. This cholesterol and phospholipid efflux process requires ABCA1.55 ABCA1 
genes are expressed in diverse organs. The early extracted cholesterol from tissues to nascent 
HDL are free cholesterol that located on the surface of HDL. To become mature HDL with 
larger size and cholesterol ester core, LCAT inside HDL transfers a fatty acid from 
phospholipids to free cholesterol which results in cholesterol ester production in the core.56 Apo 
A1 is the activator of LCAT.57 The nascent HDL with enough cholesterol ester inside then 
becomes mature HDL. Besides the cholesterol extraction in the nascent stage with the assistance 
of ABCA1, mature HDL also can extract cholesterol and phospholipid from tissues by ATP-
binding cassette transporter G1(ABCG1) and SR-B1, or even passive diffusion through the cell 
membrane.58 In addition to cholesterol and phospholipid extraction, mature HDL has 
components exchange with chylomicron and VLDL via CETP. Cholesterol esters are transferred 
from HDL to ApoB containing lipoprotein and triglycerides are transferred from ApoB 
containing lipoprotein to HDL. The triglycerides in the HDL can be hydrolyzed by hepatic 
lipase. There are basically two ways for mature HDL to deliver cholesterol to liver. First, HDL 
binds to SR-B1 on the surface of hepatocytes. SR-B1 mediates the uptake process of cholesterol 
from HDL to the liver. SR-B1 is a bidirectional receptor since it mediates both efflux and influx 
of cholesterol between HDL and tissues.59 The cholesterol empty HDL then will back into 
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circulation again. Another way for mature HDL to deliver cholesterol to liver is endocytosis 
because HDL has ApoE which can be recognized by LDL receptors on hepatocytes. All the 
components of HDL then will be utilized by liver. HDL is regarded as the beneficial micelle in 
the lipoproteins family contrary to LDL due to the reverse cholesterol transport function of HDL. 
However, besides reverse cholesterol transport, HDL also has the functions on anti-oxidation of 
LDL, vasodilatory promotion, anti-thrombosis, cell apoptosis reduction and anti-inflammation.60 
 
1.3 Lipoprotein lipase and hepatic lipase  
          Lipoprotein lipase is the enzyme mainly produced by adipose tissue and muscle. It is the 
enzyme for triglycerides hydrolysis of VLDL and chylomicron.61 In adipose tissue or muscle 
cells, inactive lipoprotein lipase is first assembled in the endoplasmic reticulum. Since 
lipoprotein lipase is a homodimer, the assembly process includes dimerization and 
glycosylation.62,63 Then the inactive assembled lipoprotein lipase is delivered to Golgi apparatus 
for activation. After activation, lipoprotein is secreted and transported to the surface of vascular 
endothelial cells. On the vascular wall, lipoprotein lipase attaches the surface by binding to 
heparin sulfate proteoglycan(HSPG), which is multifunctional glycoprotein containing 
covalently attached heparan sulfate chains.64,65 HSPG, located on the cell surfaces, has the 
functions including constituting cell membrane, maintaining proteases, and binding cytokines or 
growth factors.66 To hydrolyze triglycerides inside lipoprotein, lipoprotein lipase also requires 
ApoC2 as a co-factor. Lipoprotein lipase is regulated by diverse factors. It is regulated during 
transcription and translation processes. Life stage, fasting as well as insulin level also play an 
important role in lipoprotein lipase activity regulation. For example, there is liver expression of 
lipoprotein lipase during fetal stage of humans while there is no liver expression for adults. 
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During fasting, the lipoprotein lipase activity is low in adipose tissue while it is high in muscle 
and heart tissue. When eating, in contrast, the lipoprotein lipase activity is high in adipose tissue 
but it is relatively low in heart and muscle tissue.67 Insulin as well as glucose has the effect on 
increasing lipoprotein lipase activity in adipose tissue.68,69 Hepatic lipase is another member of 
lipolytic enzyme family which is mainly produced in the liver. Hepatic lipase is the main 
triglycerides-hydrolysis enzyme for IDL and HDL. Similar to lipoprotein lipase, hepatic lipase is 
assembled in the endoplasmic reticulum and Golgi apparatus and attached to HSPG on the 
surface of liver endothelial cells.70 But the surface of endothelial cell is not the only effective site 
of hepatic lipase, it could be dissociated by HDL and be active in the circulation system. The 
activity of circulating hepatic lipase is associated with both HDL and fasting.71,72 In the feeding 
state, most ApoE on HDL are transferred to VLDL by CETP, and the ApoE-deficient HDL has a 
high affinity to associate with hepatic lipase and release hepatic lipase from surface of liver 
endothelial cells. After releasing, the hepatic lipase associated with HDL is inactive, and its 
activation and dissociation from HDL depends on plasma electrostatic situation. When eating, 
intake of free fatty acids increases the negative charge in plasma which then promotes the 
activation and dissociation of HDL-bound hepatic lipase. While in fasting, ApoE-rich HDL has a 
low affinity to hepatic lipase and cannot release it from the surface of liver endothelial cells.73-75 
 
1.4 Fatty acids and beta oxidation 
          In people’s daily diet, fatty acids are mainly from intake of animal fats and vegetable oils. 
Fatty acids from diverse resources are divided into several types based on chemical structure. 
Fatty acids can be broadly divided into saturated fatty acids and unsaturated fatty acids based on 
whether there is double bonds in long carbon chains. Saturated fatty acids, by definition, don't 
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have any double bonds in long carbon chain. The most common saturated fatty acids are palmitic 
acid, lauric acid and stearic acid. Unsaturated fatty acids, contrary to saturated fatty acids, have 
one or more double bonds in carbon long chain, and it could be first classified by configuration. 
The unsaturated fatty acids that have trans geometric configuration are commonly referred as 
trans fats which were widely used in late twentieth century but have been recognized as harmful 
and coronary artery disease induced species in recent years. The unsaturated fatty acids that have 
cis geometric configuration could be further divided based on the numbers of double bonds in 
long carbon chain they have. Monounsaturated fatty acids have only one double bonds in their 
long carbon chain. There are two common types of monounsaturated fatty acids: omega-7 fatty 
acids and omega-9 fatty acids. Omega-7 fatty acids have the double bonds between seventh and 
eighth carbon in the long chain while omega-9 fatty acids have the double bonds between ninth 
and tenth carbon in the long chain. Common omega-7 fatty acids are palmitoleic acid and 
vaccenic acid and common omega-9 fatty acids are oleic acid and erucic acid. Polyunsaturated 
fatty acids have more than one double bonds in the long carbon chain and they are classified into 
omega-3 fatty acids and omegra-6 fatty acids based on the position of first double bonds. 
Omega-3 fatty acids have the first double bonds between third and fourth carbon in the long 
chain and common omega-3 fatty acids are alpha-linolenic acids which are from plant and 
docosahexaenoic acids(DHA) which are from fish.76 Omega-6 fatty acids have the first double 
bonds between sixth and seventh carbon in long chain and common omega-6 fatty acid is linoleic 
acid. In adipose and muscle tissue, fatty acids are mainly from hydrolysis of triglycerides 
delivered by lipoproteins, and fatty acids in these tissues whether stored as triglycerides by 
combining three fatty acids with one glycerol or go through beta-oxidation process.77 In beta-
oxidation, fatty acids with long chains are separated into several two-carbon units. Each two-
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carbon unit reacts with co-enzyme A and produce an Acetyl-CoA which reacts as the initial 
reactants in citric acid cycle to produce ATP.78,79 
 
1.5 Oxidation of fatty acids and phospholipids in lipoprotein  
          In recent research, oxidized LDL takes place of LDL and becomes a more effective 
biomarker to predict cardiovascular disease since oxidized LDL has a more direct relationship 
with macrophages and species in intima where atherosclerosis develops. Measurements and 
experiments also show significant elevations of oxidized LDL in patients with coronary artery 
disease.80,81 The surface of lipoprotein mainly consists of phospholipid that has polyunsaturated 
fatty acid tails. Since the polyunsaturated fatty acids have the high susceptibility to oxidation by 
reactive oxygen species or free radicals, the polyunsaturated fatty acid easily become fatty acid 
radical by attaching free radical. Then fatty acid radical will react with molecular oxygen and 
produce peroxyl fatty acid radical. Finally, peroxyl fatty acid radical reacts with other 
unsaturated fatty acid to produce oxidized phospholipids or reactive lipid aldehydes such as 
malondialdehyde(MDA) which are able to modify apolipoproteins such as ApoB100.82,83 LDL 
with modified apolipoproteins cannot be recognized by LDL receptors and cleared by the 
lipoprotein circulating system so eventually these LDL with modified apolipoproteins will only 
be taken up by macrophage through scavenger receptors in intima and promote the development 
of atherosclerosis. LDL also can be oxidized by specific oxidase such as 
myeloperoxidase(MPO).84 The oxidation process occurs almost always in the subendothelial 
space or intima where most antioxidant species don't exist.85 Molecular antioxidants such as 
vitamin E and enzyme antioxidant such as paraoxonases(PON) all exist and circulate in the 
plasma so it is almost impossible for LDL to be oxidized in plasma.86 
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Chapter 2. Modeling 
2.1 Overview 
          Based on the lipid metabolism in the human body, we built a model for the circulation of 
lipoproteins. This model includes liver, muscle, adipose and plasma. The liver compartment 
takes chylomicron remnant which contains mainly triglycerides and abstracts cholesterols from 
HDL that is returned from tissue. Liver is also the compartment that produces VLDL which 
delivers triglycerides from liver to tissues. Muscle and adipose tissue are the main compartments 
that take up triglycerides in VLDL/IDL/LDL and hydrolyze triglycerides into fatty acids for 
further energy synthesis or for storage. Plasma is the media transports all types of lipoprotein.  
 
Figure 1. Overall diagram of compartments in the human body 
The model includes all cholesterol-related metabolism processes and substances into a schematic 
for each tissue compartment. Based on the figure of each compartment, biology processes are 
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derived and then translated into reaction rate equations. Eventually, reaction rate equations from 
each compartment are combined and related together to develop an ODE model which is capable 





Figure 2. Diagram of liver compartment 
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          As figure 2 shows, the liver compartment is mainly divided into two sections, hepatocytes 
and hepatic capillary. In hepatic capillary, the processes included are VLDL metabolism, HDL 
metabolism and CETP exchange process. In VLDL metabolism, VLDL becomes IDL by giving 
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up triglycerides which are hydrolyzed by lipoprotein lipase, and IDL either becomes LDL by 
giving up triglycerides which are hydrolyzed by hepatic lipase, or IDL is directly endocytosed by 
LDL receptors. HDL is assembled by ApoA1 and cholesterols as well as phospholipids which 
are extracted from tissues, and eventually HDL is taken up by SR-B1. CETP transfers cholesterol 
esters from HDL to both VLDL/IDL and transfers triglycerides back to HDL from VLDL/IDL. 
In hepatocytes, the processes included are VLDL assembly, beta-oxidation and balance reaction 
among monoglycerides(MGA), diglycerides(DGA) and triglycerides. In VLDL assembly, 
triglycerides, phospholipids, cholesterol esters, cholesterols and specific apolipoproteins that 
exist in hepatocytes are utilized to synthesize VLDL. In beta-oxidation, fatty acids are utilized to 
produce Acetyl-CoA. Besides, there are also CMR/VLDL/IDL/LDL/HDL endocytosis and 
ApoA1 synthesis inside hepatocyte. 
 
2.3 Adipose tissue  
 
 
Figure 3. Diagram of adipose tissue 
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          As figure 3 shows, the adipose compartment also is divided into two sections, adipose 
tissue and adipose capillary. In adipose capillary, the processes included are VLDL metabolism, 
chylomicron metabolism and CETP exchange process. In VLDL metabolism, VLDL becomes 
IDL by giving up triglycerides which are hydrolyzed by lipoprotein lipase, and IDL either 
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becomes LDL by giving up triglycerides which are hydrolyzed by hepatic lipase, or IDL is 
directly endocytosed by receptors. Chylomicron becomes chylomicron remnant by giving up 
triglycerides which are hydrolyzed by lipoprotein lipase. CETP transfers cholesterol esters from 
HDL to both VLDL/IDL and transfers triglycerides back to HDL from VLDL/IDL. In adipose 
tissue, the processes included are beta-oxidation and balance reaction among 
monoglycerides(MGA), diglycerides(DGA) and triglycerides. In beta-oxidation, fatty acids are 




Figure 4. Diagram of muscle tissue 
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          As figure 4 shows, the muscle compartment also is divided into two sections, muscle tissue 
and muscle capillary. In muscle capillary, the processes included are VLDL metabolism, 
chylomicron metabolism and CETP exchange process. In VLDL metabolism, VLDL becomes 
IDL by giving up triglycerides which are hydrolyzed by lipoprotein lipase, and IDL either 
becomes LDL by giving up triglycerides which are hydrolyzed by hepatic lipase, or IDL is 
directly endocytosed by receptors. Chylomicron becomes chylomicron remnant by giving up 
triglycerides which are hydrolyzed by lipoprotein lipase. CETP transfers cholesterol esters from 
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HDL to both VLDL/IDL and transfers triglycerides back to HDL from VLDL/IDL. In muscle 
tissue, the processes included are beta-oxidation and balance reaction among 
monoglycerides(MGA), diglycerides(DGA) and triglycerides. In beta-oxidation, fatty acids are 



















Chapter 3. Results and Discussion 
          In daily diet, different types of fatty acids are taken is from different sources. In our model, 
palm oil, olive oil and corn oil (enriched in saturated, monounsaturated and omega-6 









fatty acids (%) 
Palm oil 49.3 37 0.2 9.1 
Olive oil  13.8 73 0.7 9.8 
Corn oil 12.9 27.6 1 58 
Table 2. Composition of different types of oil 
 
One of the most important parameters need to be determined in our model is the synthesis rate of 
VLDL and it depends on both ApoB100 production rate and the triglycerides secretion rate in the 
VLDL assembly process which we found in López-Soldado et al. (2009).87 With the intake 
amount of 40 mg for each type of oil, we derived fatty acid distribution in each organ in figure 5. 
Triglycerides in each organ reach the peak after around 2 hours of dietary intake, and muscle has 
about 4 times triglyceride as liver.  Saturated and unsaturated triglycerides in VLDL for different 




Figure 5. Number of triglycerides in organs 
 
 
Figure 6. Total and unsaturated triglycerides in oils 
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Total and unsaturated cholesterol esters for all three types of oil are shown in figure 7. Total 
cholesterol ester for three oils are the same while unsaturated cholesterol ester for palm oil is less 
than that of corn oil and olive oil. 
 
 
Figure 7. Total and unsaturated cholesterol ester in oils 
Double bonds number of three types of oil are shown in figure 8. Corn oil has the maximum 




Figure 8. Double bonds number in oils 
 
 
Figure 9 shows the oxidized double bonds in low triglyceride VLDL and figure 10 shows the 
oxidized double bonds in high triglyceride VLDL. Both in low triglyceride and high triglyceride 
VLDL, corn oil has the largest amount of oxidized double bonds while palm oil has the least 
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loading CETP + 2Saturated triglyceride  
2Cholesterol ester + Unsaturated triglyceride loading CETP                     Cholesterol ester 
loading CETP + 2Unsaturated triglyceride 
13. HDL formation 







   −
𝐝[𝐮𝐓𝐆]
𝐝𝐭











































































= 𝒌 ∗ [𝐀𝐜𝐞𝐭𝐲𝐥𝐂𝐨𝐀]3 
12.                                                     −
𝐝[𝐬𝐓𝐆]
𝐝𝐭












= 𝒌 ∗ [𝒖𝑻𝑮𝑪𝑬𝑻𝑷] ∗ [𝑪𝑬]2 
13.                                                  −
𝐝[𝐂𝐇]
𝐝𝐭
= 𝒌 ∗ [𝑪𝑯] 
 
Adipose Tissue 
1. Unsaturated triglyceride oxidation 
Unsaturated triglyceride + [o]                       oxidized triglyceride 
2. Unsaturated cholesterol ester oxidation 
Unsaturated cholesterol ester + [o]                        oxidized cholesterol ester 
3. Saturated triglyceride hydrolysis 
                                         (LPL) 
Saturated triglyceride                       3 Saturated Fatty acids + Glycerol 
4. Unsaturated triglyceride hydrolysis 
Unsaturated triglyceride                      3 Unsaturated Fatty acids + Glycerol 
5. Saturated cholesterol ester production 
Cholesterol + Saturated Fatty acid                         Saturated cholesterol ester 
6. Unsaturated cholesterol ester production 
Cholesterol + Unsaturated Fatty acid                      Unsaturated cholesterol ester 
7. MGA/DGA/TG balance 
Fatty acid + Glycerol                            Monoglyceride 
Fatty acid + Monoglyceride                            Diglyceride 
Fatty acid + Diglyceride                            Triglyceride 
8. Beta-oxidation 
Saturated Fatty acid                         nAcetyl-CoA 
Unsaturated Fatty acid                      nAcetyl-CoA 
9. Citric acid cycle 
Acetyl-CoA                        ATP 
10. CETP transfer process 
2Saturated triglyceride + Cholesterol ester loading CETP                       Saturated 
triglyceride loading CETP + 2Cholesterol ester 
2Unsaturated triglyceride + Cholesterol ester loading CETP                      Unsaturated 
triglyceride loading CETP + 2Cholesterol ester 
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2Cholesterol ester + Saturated triglyceride loading CETP                       Cholesterol ester 
loading CETP + 2Saturated triglyceride  
2Cholesterol ester + Unsaturated triglyceride loading CETP                     Cholesterol ester 
loading CETP + 2Unsaturated triglyceride 
11. HDL formation 






   −
𝐝[𝐮𝐓𝐆]
𝐝𝐭




















































= 𝒌 ∗ [𝐀𝐜𝐞𝐭𝐲𝐥𝐂𝐨𝐀] 
 
10.                                                     −
𝐝[𝐬𝐓𝐆]
𝐝𝐭













= 𝒌 ∗ [𝒖𝑻𝑮𝑪𝑬𝑻𝑷] ∗ [𝑪𝑬]2 
11.                                                          −
𝐝[𝐂𝐇]
𝐝𝐭






1. Unsaturated triglyceride oxidation 
Unsaturated triglyceride + [o]                      oxidized triglyceride 
2. Unsaturated cholesterol ester oxidation 
Unsaturated cholesterol ester + [o]                        oxidized cholesterol ester 
3. Saturated triglyceride hydrolysis 
Saturated triglyceride                      3 Saturated Fatty acids + Glycerol 
4. Unsaturated triglyceride hydrolysis 
Unsaturated triglyceride                       3 Unsaturated Fatty acids + Glycerol 
5. Saturated cholesterol ester production 
Cholesterol + Saturated Fatty acid                        Saturated cholesterol ester 
6. Unsaturated cholesterol ester production 
Cholesterol + Unsaturated Fatty acid                      Unsaturated cholesterol ester 
7. Beta-oxidation 
Saturated Fatty acid                         nAcetyl-CoA 
Unsaturated Fatty acid                       nAcetyl-CoA 
8. Citric acid cycle 
Acetyl-CoA                      ATP 
9. CETP transfer process 
2Saturated triglyceride + Cholesterol ester loading CETP                       Saturated 
triglyceride loading CETP + 2Cholesterol ester 
2Unsaturated triglyceride + Cholesterol ester loading CETP                      Unsaturated 
triglyceride loading CETP + 2Cholesterol ester 
2Cholesterol ester + Saturated triglyceride loading CETP                       Cholesterol ester 
loading CETP + 2Saturated triglyceride  
2Cholesterol ester + Unsaturated triglyceride loading CETP                     Cholesterol ester 
loading CETP + 2Unsaturated triglyceride 
10. HDL formation 







   −
𝐝[𝐮𝐓𝐆]
𝐝𝐭







































= 𝒌 ∗ [𝐀𝐜𝐞𝐭𝐲𝐥𝐂𝐨𝐀] 
 
 
9.                                                     −
𝐝[𝐬𝐓𝐆]
𝐝𝐭












= 𝒌 ∗ [𝒖𝑻𝑮𝑪𝑬𝑻𝑷] ∗ [𝑪𝑬]2 
10.                                                              −
𝐝[𝐂𝐇]
𝐝𝐭
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Summary Statement 
Chemical Engineering student with abundant research experience relevant to biochemistry field. 
Effective problem-resolver in biochemical aspect especially in metabolic biotechnology and 
pharmacology. 
Education 
University of Massachusetts, Amherst                                                                                              
Amherst, MA                                    Bachelor of Science, Chemical Engineering (GPA 3.42)                                              
January 2014 - May 2017                 Concentration: Biochemical Engineering 
Relevant Course: Probability, Statics, Calculus, Algebra, Math Modeling, Physical Chemistry, 
Kinetics and Reactor Designs, Thermodynamics, Fluid Mechanics, Heat and Mass Transfer, 
Separations, Organic Chemistry, Biochemistry for Chemists, Bioengineering, Process control, 
Process design, Tissue Engineering, Nanobiomaterials  
 
Johns Hopkins University                                                                                                                   
Baltimore, MD   Master of Science in Engineering, Chemical and Biomolecular Engineering     
September 2017 - May 2019 
Honor: ChemBE Master Second Year Scholarship (2018-2019) 
Relevant Course: Advanced Thermodynamics, Metabolic system Biotechnology, Interfacial 
Science, Advanced Chemical Reaction, Transport Phenomena, Advanced Pharmacokinetics, 
Advanced Pharmacodynamics  
Project Experience     
University of Massachusetts, Amherst, Department of Chemical Engineering                         
Amherst, MA       Bone Marrow Engineering Project                                                                            
September 2015 - May 2016 
⚫ Created and developed multi-compartment tissue model via integrating separately 
constructed and optimized individual modules in a single platform  
⚫ Supervised the model creation process, collected data and tested stability of the model 
University of Massachusetts, Amherst, Drug Delivery Lab                                                            
Amherst, MA       Research Assistant                                                                                                       
September 2015 - May 2016 
⚫ Created the in vitro devices that mimic the tissue surrounding blood vessels in tumors and 
enable measurement of diffusion, cell binding, and therapeutic outcome by understanding 
the integration of computational models, microfluidic devices, and animal models 
⚫ Organized lab instruments and utilized the software to collect lab data 
Johns Hopkins University                                                                                                                   
Baltimore, MD   Advanced Pharmacokinetics Project                                                                       
September 2017 – May 2018 
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⚫ In a three people team developed a model by MATLAB under multi-compartment 
environment to predict hepatic bioavailability with given pharmacokinetics parameters of 
drugs   
Leadership and Activities 
Heat Exchange Research Group in Senior Lab                                                                                  
Amherst, MA       Team leader                                                                                                         
September 2016-November 2016 
⚫ Distributed specific work to group members and integrated final results from research  
⚫ Made presentations and wrote final lab report 
UMass Marching Band                                                                                                                           
Amherst, MA                                                Trombone player                                                                                                                  
January 2014-May 2015 
⚫ Attended the school sports marching openings and other activities that needed marching 
band performance 
IPO (International Program Office)                                                                                                     
Amherst, MA Volunteer                                                                                                                                            
September 2016 
⚫ Participated in helping new students during International Orientation at the beginning of 
the semester 
Technical Skills          
Software:  Microsoft Office Suit (Word, Excel, PowerPoint), MATLAB, Aspen, Simulink 
Foreign Language: Chinese, Japanese 
 
